Literature DB >> 24082082

A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2.

Jacqueline M Tremblay1, Jean Mukherjee, Clinton E Leysath, Michelle Debatis, Kwasi Ofori, Karen Baldwin, Courtney Boucher, Rachel Peters, Gillian Beamer, Abhineet Sheoran, Daniela Bedenice, Saul Tzipori, Charles B Shoemaker.   

Abstract

Shiga toxin-producing Escherichia coli (STEC) is a major cause of severe food-borne disease worldwide, and two Shiga toxins, Stx1 and Stx2, are primarily responsible for the serious disease consequence, hemolytic-uremic syndrome (HUS). Here we report identification of a panel of heavy-chain-only antibody (Ab) V(H) (VHH) domains that neutralize Stx1 and/or Stx2 in cell-based assays. VHH heterodimer toxin-neutralizing agents containing two linked Stx1-neutralizing VHHs or two Stx2-neutralizing VHHs were generally much more potent at Stx neutralization than a pool of the two-component monomers tested in cell-based assays and in vivo mouse models. We recently reported that clearance of toxins can be promoted by coadministering a VHH-based toxin-neutralizing agent with an antitag monoclonal antibody (MAb), called the "effector Ab," that indirectly decorates each toxin molecule with four Ab molecules. Decoration occurs because the Ab binds to a common epitopic tag present at two sites on each of the two VHH heterodimer molecules that bind to each toxin molecule. Here we show that coadministration of effector Ab substantially improved the efficacy of Stx toxin-neutralizing agents to prevent death or kidney damage in mice following challenge with Stx1 or Stx2. A single toxin-neutralizing agent consisting of a double-tagged VHH heterotrimer--one Stx1-specific VHH, one Stx2-specific VHH, and one Stx1/Stx2 cross-specific VHH--was effective in preventing all symptoms of intoxication from Stx1 and Stx2 when coadministered with effector Ab. Overall, the availability of simple, defined, recombinant proteins that provide cost-effective protection against HUS opens up new therapeutic approaches to managing disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24082082      PMCID: PMC3837998          DOI: 10.1128/IAI.01033-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

Review 1.  Shiga toxins and apoptosis.

Authors:  Rama P Cherla; Sang-Yun Lee; Vernon L Tesh
Journal:  FEMS Microbiol Lett       Date:  2003-11-21       Impact factor: 2.742

Review 2.  Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis.

Authors:  A D O'Brien; V L Tesh; A Donohue-Rolfe; M P Jackson; S Olsnes; K Sandvig; A A Lindberg; G T Keusch
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

3.  Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor.

Authors:  A Cohen; G E Hannigan; B R Williams; C A Lingwood
Journal:  J Biol Chem       Date:  1987-12-15       Impact factor: 5.157

4.  Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies.

Authors:  A Donohue-Rolfe; D W Acheson; A V Kane; G T Keusch
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

Review 5.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  Responses of human intestinal microvascular endothelial cells to Shiga toxins 1 and 2 and pathogenesis of hemorrhagic colitis.

Authors:  M S Jacewicz; D W Acheson; D G Binion; G A West; L L Lincicome; C Fiocchi; G T Keusch
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

Review 7.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans.

Authors:  P Boerlin; S A McEwen; F Boerlin-Petzold; J B Wilson; R P Johnson; C L Gyles
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

9.  Endothelial heterogeneity in Shiga toxin receptors and responses.

Authors:  T G Obrig; C B Louise; C A Lingwood; B Boyd; L Barley-Maloney; T O Daniel
Journal:  J Biol Chem       Date:  1993-07-25       Impact factor: 5.157

10.  Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro.

Authors:  C A Lingwood; H Law; S Richardson; M Petric; J L Brunton; S De Grandis; M Karmali
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

View more
  53 in total

1.  Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.

Authors:  Abhineet S Sheoran; Igor P Dmitriev; Elena A Kashentseva; Ocean Cohen; Jean Mukherjee; Michelle Debatis; Jonathan Shearer; Jacqueline M Tremblay; Gillian Beamer; David T Curiel; Charles B Shoemaker; Saul Tzipori
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

2.  Mechanisms of Ricin Toxin Neutralization Revealed through Engineered Homodimeric and Heterodimeric Camelid Antibodies.

Authors:  Cristina Herrera; Jacqueline M Tremblay; Charles B Shoemaker; Nicholas J Mantis
Journal:  J Biol Chem       Date:  2015-09-22       Impact factor: 5.157

3.  A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.

Authors:  Zhiyong Yang; Diane Schmidt; Weilong Liu; Shan Li; Lianfa Shi; Jinliang Sheng; Kevin Chen; Hua Yu; Jacqueline M Tremblay; Xinhua Chen; Kurt H Piepenbrink; Eric J Sundberg; Ciaran P Kelly; Guang Bai; Charles B Shoemaker; Hanping Feng
Journal:  J Infect Dis       Date:  2014-03-27       Impact factor: 5.226

4.  Stepwise engineering of heterodimeric single domain camelid VHH antibodies that passively protect mice from ricin toxin.

Authors:  David J Vance; Jacqueline M Tremblay; Nicholas J Mantis; Charles B Shoemaker
Journal:  J Biol Chem       Date:  2013-11-07       Impact factor: 5.157

5.  Critical roles of Clostridium difficile toxin B enzymatic activities in pathogenesis.

Authors:  Shan Li; Lianfa Shi; Zhiyong Yang; Yongrong Zhang; Gregorio Perez-Cordon; Tuxiong Huang; Jeremy Ramsey; Numan Oezguen; Tor C Savidge; Hanping Feng
Journal:  Infect Immun       Date:  2014-11-17       Impact factor: 3.441

Review 6.  mRNA: A Novel Avenue to Antibody Therapy?

Authors:  Thomas Schlake; Moritz Thran; Katja Fiedler; Regina Heidenreich; Benjamin Petsch; Mariola Fotin-Mleczek
Journal:  Mol Ther       Date:  2019-03-06       Impact factor: 11.454

7.  A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model.

Authors:  Mahtab Moayeri; Clinton E Leysath; Jacqueline M Tremblay; Catherine Vrentas; Devorah Crown; Stephen H Leppla; Charles B Shoemaker
Journal:  J Biol Chem       Date:  2015-01-06       Impact factor: 5.157

8.  The molecular mechanism of Shiga toxin Stx2e neutralization by a single-domain antibody targeting the cell receptor-binding domain.

Authors:  Alvin W H Lo; Kristof Moonens; Maia De Kerpel; Lea Brys; Els Pardon; Han Remaut; Henri De Greve
Journal:  J Biol Chem       Date:  2014-07-22       Impact factor: 5.157

9.  Identification of Nanobodies Blocking Intimate Adherence of Shiga Toxin-Producing Escherichia coli to Epithelial Cells.

Authors:  David Ruano-Gallego; Luis Ángel Fernández
Journal:  Methods Mol Biol       Date:  2021

10.  Adenoviral Expression of a Bispecific VHH-Based Neutralizing Agent That Targets Protective Antigen Provides Prophylactic Protection from Anthrax in Mice.

Authors:  Mahtab Moayeri; Jacqueline M Tremblay; Michelle Debatis; Igor P Dmitriev; Elena A Kashentseva; Anthony J Yeh; Gordon Y C Cheung; David T Curiel; Stephen Leppla; Charles B Shoemaker
Journal:  Clin Vaccine Immunol       Date:  2016-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.